Premium
We Use Bioincompatible Peritoneal Dialysis Solutions
Author(s) -
Troidle Laura,
Hansson Joni,
Juergensen Peter,
Finkelstein Fredric O.
Publication year - 2016
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12490
Subject(s) - peritoneal dialysis , biocompatible material , medicine , limiting , intensive care medicine , nephrology , dialysis , renal function , end stage renal disease , urology , disease , biomedical engineering , mechanical engineering , engineering
Despite advances in peritoneal dialysis ( PD ) technique and therapy over the last 40 years, PD therapy for end‐stage renal disease ( ESRD ) in the United States remains underutilized. One of the major factors contributing to this underutilization involves concerns about technique failure. More physiologic PD solutions, with a lower concentration of glucose degradation products and a neutral pH , exist and are readily available in Europe, Asia, and Australia. Several benefits of these biocompatible solutions exist over the conventional solutions including a slower decline in residual renal function and better maintenance of urine volumes. There may also be a beneficial effect of the biocompatible solutions in limiting the increase in peritoneal transport that is characteristic of patients maintained on conventional solutions. It should be of concern to the US nephrology community that biocompatible PD solutions are unavailable in the United States.